Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Stockholm - Delayed Quote SEK

Spermosens AB (SPERM.ST)

Compare
0.0092
+0.0004
+(4.55%)
At close: April 4 at 5:08:51 PM GMT+2
Loading Chart for SPERM.ST
  • Previous Close 0.0088
  • Open 0.0090
  • Bid 0.0084 x --
  • Ask 0.0092 x --
  • Day's Range 0.0084 - 0.0092
  • 52 Week Range 0.0062 - 0.2090
  • Volume 5,528,566
  • Avg. Volume 14,118,318
  • Market Cap (intraday) 12.344M
  • Beta (5Y Monthly) -0.37
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Spermosens AB provides diagnostic health care products and services in Sweden. The company offers male infertility fertility diagnostics and fertility treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB was incorporated in 2018 and is based in Lund, Sweden.

www.spermosens.com

3

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SPERM.ST

View More

Performance Overview: SPERM.ST

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

SPERM.ST
31.34%
OMX Stockholm 30 Index (^OMX)
7.89%

1-Year Return

SPERM.ST
94.52%
OMX Stockholm 30 Index (^OMX)
9.30%

3-Year Return

SPERM.ST
99.92%
OMX Stockholm 30 Index (^OMX)
7.06%

5-Year Return

SPERM.ST
99.83%
OMX Stockholm 30 Index (^OMX)
62.84%

Compare To: SPERM.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SPERM.ST

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    12.34M

  • Enterprise Value

    11.91M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.45

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.04%

  • Return on Equity (ttm)

    -50.97%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.2M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    659k

  • Total Debt/Equity (mrq)

    0.84%

  • Levered Free Cash Flow (ttm)

    -12.55M

Research Analysis: SPERM.ST

View More

Company Insights: SPERM.ST

Research Reports: SPERM.ST

View More